Advertisement

Topics

Latest "Marketed Nasal Strip Placebo Nasal Strip Prototype Nasal" News Stories - Page: 3

06:19 EST 19th February 2019 | BioPortfolio

Here are the most relevant search results for "Marketed Nasal Strip Placebo Nasal Strip Prototype Nasal" found in our extensive news archives from over 250 global news sources.

More Information about Marketed Nasal Strip Placebo Nasal Strip Prototype Nasal on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Marketed Nasal Strip Placebo Nasal Strip Prototype Nasal for you to read. Along with our medical data and news we also list Marketed Nasal Strip Placebo Nasal Strip Prototype Nasal Clinical Trials, which are updated daily. BioPortfolio also has a large database of Marketed Nasal Strip Placebo Nasal Strip Prototype Nasal Companies for you to search.

Showing "Marketed Nasal Strip Placebo Nasal Strip Prototype Nasal" News Articles 51–75 of 2,400+

Wednesday 13th February 2019

Janssen’s nasal spray for depression clears FDA committee


Postdischarge MRSA Decolonization Cut Infection Risk

(MedPage Today) -- Patients used antiseptic soap, mouthwash, nasal ointment for 6 months

Antidepressant made with party drug gets FDA panel’s backing

An experimental nasal spray developed by Johnson & Johnson to treat depression could be headed for FDA approval.


FDA Panels Endorse Ketamine Spray for Resistant Depression

Two FDA panels jointly recommended esketamine 28-mg single-use nasal spray for the patients with treatment-resistant depression. News Alerts

A randomised controlled trial of nasal decongestant to treat obstructive sleep apnoea in people with cervical spinal cord injury

FDA Warns Korean Firm Soleo For GMP Violations, Unapproved Shampoo Drug

Soleo’s Marum GENtLE THERAPY Shampoo, marketed as an anti-dandruff and hair-growth treatment, is an unapproved new drug, according to FDA...   

Ironwood Pharmaceuticals Provides Fourth Quarter and Full Year 2018 Investor Update

– Grew 2018 revenue 16% year-over-year to $347 million, driven primarily by U.S. LINZESS® (linaclotide) collaboration revenue of $264 million and linaclotide API sales of $70 million – – Progressed separation of Ironwood and Cyclerion into two publicly-traded companies with completion expected first half 2019 – – Advance...

Aspartame and artificial sweeteners – helping or hindering weight loss?

Science blog With our appetite for low or zero sugar products increasing, artificial sweeteners are big business. Food or drinks containing artificial sweeteners are often marketed as a healthier option, and it’s understandable why. Because artificial sweeteners are significantly sweeter than sugar, they can be used in very small amounts and contribute little to no calories. There are lots of...

FDA panel backs J&J's potential depression blockbuster

A panel of advisers to the FDA has voted in favour of approving Johnson & Johnson’s experimental nasal spray for depression, esketamine, bringing the medicine closer to approval. Votes from the FDA’s panel are not binding, but the regulator us...

Janssen's esketamine drug recommended by FDA panel for depression

In a rare and welcomed development in the treatment of major depressive disorder (MDD), Janssen has announced that its esketamine nasal spray Spravato has been recommended by the FDA’s Psychopharmacologic Drug Advisory Committee and Drug Safety and Risk Management Advisory Committee for the treatment of treatment-resistant depression. The panel voted overwhelmingly in favour of the drug, with 14...

Spravato gets FDA Advisory Committee approval

FDA advisory committees have jointly voted in favour of approving Janssen's Spravato nasal spray CIII for adults living with treatment-resistant depression.

MMJ Files FDA Fast Track Approval Application For Cannabis Multiple Sclerosis Drug

FDA grants Fast Track Designation to help expedite the review and approval of drugs in development that treat serious or life threatening diseases and fill an unmet medical need. MMJ International Holdings will be one of the world’s first natural plant-derived cannabinoid prescription drugs once approved by the FDA for the treatment of spasticity and pain due to multiple sclerosis. RESTON, Va. (...

Spinal fusion procedures questioned by global task force

There is little to no evidence that two surgical procedures used to fuse crumbled vertebrae after a spinal fracture caused by osteoporosis reduce pain any better than non-surgical or placebo procedures, according to a new report in the Journal of Bone and Mineral Research. The task force looked into the most commonly used procedures to […] The post Spinal fusion procedures questioned by glob...

Tuesday 12th February 2019

FDA panel supports Janssen’s esketamine nasal spray for depression

Janssen Pharmaceutical has secured recommendation from the US Food and Drug Administration (FDA) advisory committees for the approval of its...Read More... The post FDA panel supports Janssen’s esketamine nasal spray for depression appeared first on Pharmaceutical Technology.

J&J’s Esketamine Clears Advisory Panel Hurdle for Depression Treatment

On Tuesday, a U.S. Food and Drug Administration advisory panel overwhelmingly supported approval of the nasal spray treatment.

Ketamine-like nasal spray for depression recommended by FDA panel

Experimental nasal spray is intended for people with severe depression who aren't helped by other treatments or therapies.

Johnson & Johnson's nasal spray for depression wins FDA panel backing

An advisory panel to the U.S. Food and Drug Administration on Tuesday voted in favor of Johnson & Johnson's experimental nasal spray, which has a compound similar to often-abused ketamine, bringing the drug closer to approval.

Exelixis Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update

- Total Revenue of $228.6 million for the Fourth Quarter of 2018, $853.8 million for the Full Year 2018 - - Cabozantinib Franchise Net Product Revenue of $176.2 million for the Fourth Quarter of 2018, $619.3 million for the Full Year 2018 - - GAAP Diluted EPS of $1.15 for the Fourth Quarter of 2018, $2.21 for the Full Year 2018 - ...

Myomo, Inc. Announces Closing of Public Offering and Full Exercise of Over-Allotment Option

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today has closed its previously announced underwritten public offering of 3,950,000 shares of common stock at an offering price of $1.40 per sh...

Moderna Announces Positive Interim Phase 1 Data for First Combination Vaccine Against the Respiratory Viruses hMPV and PIV3

Interim data show vaccination with mRNA-1653 boosted serum neutralization titers against hMPV and PIV3 at all dose levels tested and was generally well tolerated Company plans to advance mRNA-1653 into a Phase 1b study in seropositive pediatric subjects Conference call to be held at 5:00 p.m. ET today Moderna, Inc., (Nasdaq: MR...

CBD nasal spray Rhinodol launches

New Leaf

Tidal volume transmission during non-synchronized nasal intermittent positive pressure ventilation via RAM® cannula

U.S. FDA panel recommends approval of Johnson & Johnson's depression drug

An advisory panel to the U.S. Food and Drug Administration on Tuesday recommended Johnson & Johnson's experimental nasal spray, which has a compound similar to often-abused ketamine, for patients suffering from depression.

FDA Panel Endorses Esketamine for Depression

(MedPage Today) -- Fast-acting nasal spray wins overwhelming support

Gilead’s Selonsertib Fails to Meet Primary Endpoint in Phase 3 NASH Study

FOSTER CITY, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) today announced that STELLAR-4, a Phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of selonsertib, an investigational, once-daily, oral inhibitor of apoptosis signal-regulating kinase 1 (ASK1), in patients with compensated cirrhosis (F4) due to nonalcoholic steatohepat...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks